Excentis announces its brand new ByteBlower 2100 IP testing tool at the Anga Cable show from June 12 till 14, 2012.
Excentis launched a brand-new service for testing Wi-Fi access points. The unique testing approach in a real-world environment, a first in Europe, provides both operators and manufacturers with representative parameters for assessing the performance of Wi-Fi access points.
From December 10 till 14, 2012, eleven vendors (Broadcom Corporation, Casa Systems, Compal Broadband Networks, Hitron Technologies, Incognito Software, Intel, IPgallery, Motorola Mobility, Sinicnet, Technicolor, Ubee Interactive) tested their EuroPacketCable 2.0 products in Excentis' labs to successfully demonstrate interoperability and capabilities of the products.
Read what's new and what has changed for you.
Excentis has a new Support Portal, including a ticketing system and knowledge base.
Now is the time to learn DOCSIS 3.1. Still seats available on March 24 and 25.
Starting from European Certification Wave 55 (ECW55), the management of the EuroDOCSIS™ 2.0/3.0 and EuroPacketCable™ 1.5 certification processes has moved from Cable Europe Labs to CableLabs ® . Although Excentis keeps on performing the testing , several things do change for submitting vendors...
This year at ANGA COM, Wim De Ketelaere will share insights into the newest Wi-Fi technologies during the “Wi-Fi – Key to new business session” on May 21st, 2014. Instead of a theoretical explanation on the operation of the latest Wi-Fi technologies , Wim will present how the different technologies...
A while ago, Excentis launched a standalone LTE Immunity certification test program. The objective of this program is to ensure that cable services are not disturbed by electromagnetic fields generated by wireless equipment (currently LTE devices) using the 790-862 MHz sub-band of the digital dividend frequencies.
The EuroCableCertification Board recently granted EuroDOCSIS 2.0/ EuroDOCSIS 3.0/ EuroPacketCable 1.5 Certified status to six new products, based on testing performed by Excentis.